Haleon plc (NYSE:HLN) Sees Large Decrease in Short Interest

Haleon plc (NYSE:HLN - Get Free Report) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 7,910,000 shares, a decline of 22.8% from the October 15th total of 10,240,000 shares. Based on an average daily volume of 5,230,000 shares, the days-to-cover ratio is currently 1.5 days. Currently, 0.2% of the shares of the stock are sold short.

Hedge Funds Weigh In On Haleon

A number of large investors have recently added to or reduced their stakes in HLN. FMR LLC increased its position in shares of Haleon by 5.8% during the third quarter. FMR LLC now owns 104,918,269 shares of the company's stock valued at $1,110,035,000 after acquiring an additional 5,768,117 shares in the last quarter. Clearbridge Investments LLC increased its stake in Haleon by 8.6% in the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company's stock worth $344,888,000 after buying an additional 3,307,009 shares in the last quarter. Sculptor Capital LP lifted its holdings in shares of Haleon by 67.8% in the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company's stock worth $73,407,000 after buying an additional 3,592,000 shares in the last quarter. Douglas Lane & Associates LLC increased its holdings in shares of Haleon by 1.6% in the second quarter. Douglas Lane & Associates LLC now owns 8,533,768 shares of the company's stock worth $70,489,000 after purchasing an additional 131,892 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in shares of Haleon by 2.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 7,572,548 shares of the company's stock worth $62,549,000 after acquiring an additional 196,843 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.

Wall Street Analyst Weigh In

HLN has been the topic of several recent analyst reports. The Goldman Sachs Group lowered shares of Haleon from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 6th. Berenberg Bank initiated coverage on Haleon in a research note on Tuesday, August 6th. They issued a "buy" rating for the company. Morgan Stanley upped their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a report on Friday, September 20th. Finally, UBS Group upgraded Haleon to a "strong-buy" rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $10.95.

Haleon Stock Performance

NYSE HLN traded up $0.08 during trading on Friday, hitting $9.39. 6,227,277 shares of the company's stock traded hands, compared to its average volume of 5,273,700. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon has a 12-month low of $7.89 and a 12-month high of $10.80. The stock has a market capitalization of $42.51 billion, a price-to-earnings ratio of 27.34, a PEG ratio of 2.79 and a beta of 0.30. The business has a 50 day moving average of $10.12 and a 200-day moving average of $9.33.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.